Ocuphire is developing a “pipeline within a product” for its lead ophthalmic drug candidate Nyxol. The most advanced front-of-the-eye clinical programs target night vision disturbances and glaucoma. Nyxol has been tested in 114 subjects across five randomized, double-blind placebo-controlled Phase 1 and 2 trials. Nyxol is being advanced through the 505(b)(2) new drug application pathway in the United States and is covered by a broad global patent estate fully owned by Ocuphire, protecting the novel eye drop formulation and methods of use through at least 2034.

We are interested in adding novel ophthalmic early- to mid-stage clinical drug candidates to our portfolio. Please contact us to discuss business development opportunities.